Cue生物制药 CUE 深 沪
等待开盘 02-06 09:30:00 美东时间
0.3161
+0.007
+2.23%
华盛通- 最 高0.3175
- 今 开0.3036
- 成交量 39.86万股
- 最 低 0.2901
- 昨 收 0.3092
- 总市值 2884.02万
- 52周最高 1.54
- 市盈率 静 --
- 换手率 0.44%
- 52周最低 0.2302
- 委 比 -84.51%
- 总股本 9123.77万
- 历史最高 31.69
- 量 比 0.80
- 振 幅 8.86%
- 历史最低 0.2302
- 每 手 1
- 风险率 0.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Greenwich LifeSciences (NASDAQ:GLSI) shares rose 48.6% to $33.13 durin...
01-22 20:05
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock increased by 25.5% to $25.9...
2025-12-30 01:05
Cue Biopharma shares are trading lower after the company announced a proposed public offering.
Cue Biopharma shares are trading lower after the company announced a proposed p...
2025-12-19 05:03
Cue Biopharma Announces Proposed Public Offering
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, announced it is commencing an underwritten public offering of its common stock and accompanying warrants. The offering also includes an option for underwriters to purchase up to an additional 15% of the shares or warrants. The offering is subject to market conditions and SEC approval. H.C. Wainwright & Co. is the sole book-running manager, and Newbridge Securities Corporation is the...
2025-12-18 21:02
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Kazia Therapeutics (NASDAQ:KZIA) shares increased by 51.6% to $8.73 du...
2025-11-19 20:05
ImmunoScape Announces Exclusive In-Licensing Deal With Cue Biopharma To Lead Development Of Distinct Therapies To Attack Solid Tumor Cancers
"Seed-and-Boost" Approach with Breakthrough Potential, Poised to Transform the Cancer Immunotherapy LandscapeImmunoScape Pte. Ltd., an A*STAR spin out backed by Amgen Ventures and EDBi that is developing
2025-11-14 02:14
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors
Cue Biopharma和ImmunoScape达成合作，开发基于“Seed-and-Boost”策略的T细胞疗法，旨在通过Cue的Immuno-STAT分子与ImmunoScape的TCR结合，改善实体瘤治疗效果。该方法利用少量工程化T细胞实现体内扩增，减少毒性并简化制造流程，临床前数据支持其潜力，计划于2027年提交IND申请。Cue获1500万美元前期付款及ImmunoScape40%股权，未来还将获得销售分成。
2025-11-06 13:00
Cue Energy Highlights Sustainable Growth and Shareholder Returns at AGM
The latest announcement is out from Cue Energy Resources Limited ( ($AU:CUE) )....
2025-10-22 07:18
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Aditxt (NASDAQ:ADTX) shares increased by 28.3% to $0.89 during Thursda...
2025-10-10 05:06
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates
Cue Biopharma appoints Usman Azam, M.D., as President and CEO, with Daniel Passeri transitioning to Strategic Advisor. The company prioritizes autoimmune disease, focusing on advancing its lead candidate, CUE-401, a tolerogenic biologic. Dr. Azam brings over 25 years of experience in drug development, including leadership roles at prominent biopharma companies. He aims to drive CUE-401’s clinical development, addressing unmet needs in autoimmune ...
2025-09-29 13:00
